Bio-Techne Stock

Bio-Techne Revenue

The The revenue of Bio-Techne (TECH) as of Aug 16, 2026 is 1.22 B USD. In the previous year, The revenue was 1.22 B USD — a change of -0.38% (lower).

Revenue

1.22 BUSD

YoY

-0.38%

Last updated:

In 2026, Bio-Techne's sales reached 1.22 B USD, a -0.38% difference from the 1.22 B USD sales recorded in the previous year.

Revenue has compounded at 9.3% per year over the past 19 years to 1.22 B USD.

The Bio-Techne Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (B USD)
GROSS MARGIN (%)
Date
REVENUE (B USD)
GROSS MARGIN (%)
Jan 1, 2023
1.14 base
67.72 base
Jan 1, 2024
1.16 base
66.41 base
Jan 1, 2025
1.22 base
64.80 base
Jan 1, 2026
1.22 base
65.77 base
Jan 1, 2027 (e)
1.26 base
63.22 base
Jan 1, 2028 (e)
1.38 base
57.78 base
Jan 1, 2029 (e)
1.51 base
52.79 base
Jan 1, 2030 (e)
1.56 base
51.24 base
YEARREVENUE (B USD)GROSS MARGIN (%)
2030 est 1.5651.24
2029 est 1.5152.79
2028 est 1.3857.78
2027 est 1.2663.22
2026 1.2265.77
2025 1.2264.80
2024 1.1666.41
2023 1.1467.72
2022 1.1168.42
2021 0.9367.97
2020 0.7465.41
2019 0.7166.31
2018 0.6467.21
2017 0.5666.53
2016 0.5067.46
2015 0.4567.94
2014 0.3670.27
2013 0.3174.41
2012 0.3174.96
2011 0.2977.57
2010 0.2779.76
2009 0.2678.98
2008 0.2679.45
2007 0.2279.12
Access this data via the Eulerpool API

Bio-Techne Revenue

Bio-Techne Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.14 B USD
306.75 M USD
285.26 M USD
Jan 1, 2024
1.16 B USD
206.69 M USD
168.11 M USD
Jan 1, 2025
1.22 B USD
106.97 M USD
73.40 M USD
Jan 1, 2026
1.22 B USD
251.89 M USD
181.86 M USD
Jan 1, 2027 (e)
1.26 B USD
258.96 M USD
326.38 M USD
Jan 1, 2028 (e)
1.38 B USD
283.85 M USD
370.22 M USD
Jan 1, 2029 (e)
1.51 B USD
310.66 M USD
427.24 M USD
Jan 1, 2030 (e)
1.56 B USD
320.11 M USD
424.85 M USD

Bio-Techne Margins

Bio-Techne stock margins

The Bio-Techne margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio-Techne. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio-Techne.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
67.72 %
26.99 %
25.10 %
Jan 1, 2024
66.41 %
17.83 %
14.50 %
Jan 1, 2025
64.80 %
8.77 %
6.02 %
Jan 1, 2026
65.77 %
20.73 %
14.97 %
Jan 1, 2027 (e)
65.77 %
20.49 %
25.82 %
Jan 1, 2028 (e)
65.77 %
20.53 %
26.77 %
Jan 1, 2029 (e)
65.77 %
20.53 %
28.23 %
Jan 1, 2030 (e)
65.77 %
20.53 %
27.24 %

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Bio-Techne's Sales Figures

The sales figures of Bio-Techne originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Bio-Techne’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Bio-Techne's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Bio-Techne’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Bio-Techne stock

The revenue of Bio-Techne is 1.22 B USD in 2026.

The revenue of Bio-Techne changed from 1.22 B USD to 1.22 B USD, representing a -0.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The revenue Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Bio-Techne historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Bio-Techne

All Key Metrics — Bio-Techne